<DOC>
	<DOCNO>NCT00616031</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel carboplatin , work different way stop growth tumor cell , either kill cell stop dividing . Nitroglycerin may help carboplatin paclitaxel work well make tumor cell sensitive drug . PURPOSE : This phase II randomize trial study well give nitroglycerin together paclitaxel carboplatin work compare give paclitaxel carboplatin alone treat patient previously untreated stage III stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Paclitaxel Carboplatin With Without Nitroglycerin Treating Patients With Previously Untreated Stage III Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To evaluate tumor response rate safety nitroglycerin potentiator anticancer combination therapy comprise paclitaxel carboplatin patient previously untreated stage IIIB IV non-small cell lung cancer . OUTLINE : This multicenter , randomize , control study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive nitroglycerin , paclitaxel , carboplatin . - Arm II : Patients receive paclitaxel carboplatin . In arm , treatment continue 6 course absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Nitroglycerin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer Stage IIIB IV disease treat radical irradiation Tumor lesion must objectively evaluate accord WHO criteria ( maximum diameter shorter twice slice width short 10 mm ) CT scan No brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 01 Life expectancy ≥ 3 month Neutrophil count &gt; 2,000/μL Hemoglobin &gt; 10.0 g/dL Platelet count &gt; 100,000/μL Serum bilirubin &lt; 2.0 mg/dL ALT AST &lt; 100 IU/L Serum creatinine &lt; 2.0 mg/dL PaO_2 ≥ 70 mm Hg No cardiac problem , include follow : Poorly control hypertension Unstable angina Congestive heart failure Myocardial infarction within past year Ventricular arrhythmia require treatment except single , wellcontrolled isolated ventricular extrasystole No chronic active hepatitis cirrhosis require treatment except hepatitis virus carrier need treatment No comorbidity interstitial pneumonia pulmonary fibrosis require treatment No cancer require treatment except malignant tumor curatively resect recurrence No severe psychiatric disorder include schizophrenia dementia Cardiothoracic ratio &lt; 60 % chest xray No history severe drug allergy allergy polyoxyethylene castor oil ( anesthetic drug muscle relaxant ) polysorbate 80 Patients nitroglycerin preparation contraindicate eligible , include follow : Severe hypotension ( e.g. , systolic blood pressure ≤ 80 mm Hg ) Angleclosure glaucoma History hypersensitivity nitrate/nitrite ester drug Not pregnant nursing PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy Pleurodesis consider chemotherapy At least 1 week since prior concurrent nitric oxide donor ( e.g. , nitroglycerin ) At least 1 week since prior concurrent calcium antagonist At least 1 week since prior concurrent drug erectile dysfunction inhibit phosphodiesterase 5 ( e.g. , sildenafil citrate vardenafil hydrochloride hydrate ) More 24 hour since prior concurrent administration follow : Antifungal azoles , include ketoconazole , miconazole , itraconazole Macrolides , include erythromycin clarithromycin Cyclosporines Benzodiazepines , include diazepam , triazolam , midazolam Vitamin A Steroid hormone , include ethinylestradiol No concurrent participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>